Mitral valve prolapse and left ventricular remodelling

Mechanistic insights in mitral valve prolapse and associated left ventricular remodelling: Barlow’s Disease versus Fibroelastic Deficiency

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22130

Enrollment

200

Registered

2021-08-04

Start date

2021-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart valve disease: mitral valve prolapse

Interventions

Observational study with minimal amount of investigations, only once: - 3D echocardiography (usually in clinical routine) - Cardiac magnetic resonance scan - 24h holter monitoring - Blood sample for g

Eligibility

Inclusion criteria

Inclusion criteria: * Non-syndromic mitral valve prolapse (e.g. no Marfan syndrome) * Age 18-80 years old

Exclusion criteria

Exclusion criteria: * History of cardiac surgery * Concomitant valve disease (grade ‘moderate’ or ‘severe’) * Ischaemic heart disease * Hypertrophic cardiomyopathy * Intra-cardiac device * History of myocarditis * Left bundle branch block * Chronic kidney disease stage 4-5 * Pregnancy

Design outcomes

Primary

Measure	Time frame
1) Difference in LV volume, prolapse volume and MR volume in patients with BD versus FED, measured by echocardiography and CMR.	—

Secondary

Measure	Time frame
2) Difference in genetic variants (incl. CMP and MVP genes) in patients with BD versus FED 3) Difference in ventricular arrhythmias on 24h-holter in patients with BD versus FED, in association with LV fibrosis	—

Contacts

Public ContactLobke Pype

University Hospital Antwerp

lobke.pype@uantwerpen.be+3238212196

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)